Protara Therapeutics, Inc.(TARA)Stock Analysis
AI analysis on 2,800+ stocks →Deep AI analysis on 2,800+ stocks →13F Pro Quality Score
Not in ranked universe
Below size threshold
Below the main board's size threshold of $25M annual revenue or $100M total assets. This company reported $2.9M in revenue and is scored on the micro-cap board instead.
Financial data, filings, and institutional holdings below are still tracked in full — only the proprietary quality composite is unavailable for this name.
TARA Stock Analysis & AI Quality Score
Data updated 2026-07-26AI stock analysis and institutional research for Protara Therapeutics, Inc. (TARA), a Healthcare sector company. TARA is not currently included in 13F Pro's AI-ranked quality universe — below the main board's size threshold of $25m annual revenue or $100m total assets. this company reported $2.9m in revenue and is scored on the micro-cap board instead. Top institutional holders of TARA by reported 13-F value include Jupiter Topco, BlackRock, MILLENNIUM MANAGEMENT, based on the most recent SEC filings. TARA trades on the Nasdaq exchange and files with the SEC under CIK 1359931. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate TARA daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for Protara Therapeutics, Inc. directly from SEC EDGAR.
Net Income
Q2 2026
$-21.7M
ROIC
Q2 2026
-57.8%
Revenue & Net Income
Earnings Per Share
Key Financials Over Time
Export Financial Table · ProNet Income
-28.8% YoYOperating Income
-31.3% YoYEPS (Diluted)
+38.2% YoYTotal Assets
+15.4% YoYTotal Debt
Op. Cash Flow
-57.4% YoYFree Cash Flow
-57.4% YoY| Metric | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
| Net Income | $-57.4M -28.8% | $-44.6M -10.3% | $-40.4M +38.7% | $-66.0M -39.6% | $-47.3M -39.1% | $-34.0M |
| Operating Income | $-64.5M -31.3% | $-49.2M -12.7% | $-43.6M +35.0% | $-67.1M -41.2% | $-47.5M -37.9% | $-34.4M |
| EPS (Diluted) | $-1.34 +38.2% | $-2.17 +39.2% | $-3.57 +39.1% | $-5.86 -39.2% | $-4.21 | — |
| Total Assets | $209.5M +15.4% | $181.5M +129.8% | $79.0M -30.3% | $113.3M -34.4% | $172.6M -15.0% | $203.2M |
| Total Debt | — | — | — | — | $0.00 | $0.00 |
| Operating Cash Flow | $-56.4M -57.4% | $-35.8M +4.7% | $-37.6M -42.0% | $-26.5M +23.3% | $-34.5M -47.4% | $-23.4M |
| Free Cash Flow | $-56.5M -57.4% | $-35.9M +4.6% | $-37.6M -41.5% | $-26.6M +24.3% | $-35.1M -44.5% | $-24.3M |
Get alerted when TARA's score changes
Free account: watchlist tracking, the daily AI brief, and the AI screener.
Available Research
13F Pro tracks comprehensive data for Protara Therapeutics, Inc. including:
Top Institutional Holders of TARA
Jupiter Topco LLC
$17.9M4,696,709 shBlackRock, Inc.
$14.0M3,663,499 shMILLENNIUM MANAGEMENT LLC
$11.8M3,101,166 shVelan Capital Investment Management LP
$10.9M2,844,652 shVANGUARD CAPITAL MANAGEMENT LLC
$8.8M2,300,133 shBlackstone Inc.
$8.7M2,265,514 shORBIMED ADVISORS LLC
$8.5M2,220,000 shSio Capital Management, LLC
$7.3M1,921,872 shACORN CAPITAL ADVISORS, LLC
$6.7M1,752,115 shIntegral Health Asset Management, LLC
$5.7M1,500,000 sh
| Fund | Value | Shares |
|---|---|---|
| Jupiter Topco LLC | $17.9M | 4,696,709 |
| BlackRock, Inc. | $14.0M | 3,663,499 |
| MILLENNIUM MANAGEMENT LLC | $11.8M | 3,101,166 |
| Velan Capital Investment Management LP | $10.9M | 2,844,652 |
| VANGUARD CAPITAL MANAGEMENT LLC | $8.8M | 2,300,133 |
| Blackstone Inc. | $8.7M | 2,265,514 |
| ORBIMED ADVISORS LLC | $8.5M | 2,220,000 |
| Sio Capital Management, LLC | $7.3M | 1,921,872 |
| ACORN CAPITAL ADVISORS, LLC | $6.7M | 1,752,115 |
| Integral Health Asset Management, LLC | $5.7M | 1,500,000 |
More Healthcare Companies
View all Healthcare →Put TARA on your watchlist
Track score changes the day Protara Therapeutics, Inc. files with the SEC, follow the hedge funds that own it, screen 2,800+ AI-scored stocks, and get the daily brief — free.
Free tier includes 13F data, economic indicators, and market overview. Pro starts at $6.67/mo (billed annually).
Popular Research
Is TARA a good stock to buy?
13F Pro's AI-powered analysis of Protara Therapeutics, Inc. (TARA) draws on SEC EDGAR-sourced fundamentals, institutional 13F holdings, and insider Form 4 transactions in the Healthcare sector (listed on Nasdaq). The 32-signal AI Quality Score, current rank, and full bull/bear verdict for TARA are available on the TARA stock profile dashboard — with the same data, AI insights, ratios, and institutional activity refreshed after every 10-K, 10-Q, 13F, and Form 4 filing. TARA is classified as a small company.
Which hedge funds own TARA?
Institutional investors are required to disclose their holdings quarterly via SEC Form 13F. 13F Pro aggregates these filings to show which hedge funds, mutual funds, and asset managers are buying or selling TARA. Combined with insider transaction data from Form 4 filings and AI-powered analysis from 10 specialized research agents, 13F Pro provides a comprehensive view of Protara Therapeutics, Inc.'s investment landscape.